CMRX - CHIMERIX INC
IEX Last Trade
3.49
0.105 3.009%
Share volume: 11,709
Last Updated: Fri 27 Dec 2024 04:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$3.38
0.11
3.10%
Fundamental analysis
12%
Profitability
0%
Dept financing
3%
Liquidity
75%
Performance
10%
Performance
5 Days
10.60%
1 Month
269.43%
3 Months
269.67%
6 Months
279.55%
1 Year
254.38%
2 Year
94.19%
Key data
Stock price
$3.49
DAY RANGE
$3.30 - $3.61
52 WEEK RANGE
$0.81 - $3.39
52 WEEK CHANGE
$264.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Michael A. Sherman
Region: US
Website: chimerix.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: chimerix.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Chimerix, Inc. develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
Recent news